Utilization of Pharmacological Ascorbate to Enhance Hydrogen Peroxide-Mediated Radiosensitivity in Cancer Therapy

Interest in the use of pharmacological ascorbate as a treatment for cancer has increased considerably since it was introduced by Cameron and Pauling in the 1970s. Recently, pharmacological ascorbate has been used in preclinical and early-phase clinical trials as a selective radiation sensitizer in c...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-10, Vol.22 (19), p.10880
Main Authors: Mehdi, Zain, Petronek, Michael S., Stolwijk, Jeffrey M., Mapuskar, Kranti A., Kalen, Amanda L., Buettner, Garry R., Cullen, Joseph J., Spitz, Douglas R., Buatti, John M., Allen, Bryan G.
Format: Article
Language:English
Subjects:
Ascorbic acid
Brain cancer
Breast cancer
Cancer
Cancer therapies
Cell death
Chemotherapy
Clinical trials
Cytotoxicity
DNA damage
Glioblastoma
Glioblastoma cells
Hydrogen peroxide
Kidney cancer
Lung cancer
Lymphoma
Metastasis
Pancreatic cancer
Patients
pharmacological ascorbate
Pharmacology
Radiation
Radiation damage
Radiation effects
radiation therapy
Radiosensitivity
radiosensitization
Radiosensitizers
reactive oxygen species
Review
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interest in the use of pharmacological ascorbate as a treatment for cancer has increased considerably since it was introduced by Cameron and Pauling in the 1970s. Recently, pharmacological ascorbate has been used in preclinical and early-phase clinical trials as a selective radiation sensitizer in cancer. The results of these studies are promising. This review summarizes data on pharmacological ascorbate (1) as a safe and efficacious adjuvant to cancer therapy; (2) as a selective radiosensitizer of cancer via a mechanism involving hydrogen peroxide; and (3) as a radioprotector in normal tissues. Additionally, we present new data demonstrating the ability of pharmacological ascorbate to enhance radiation-induced DNA damage in glioblastoma cells, facilitating cancer cell death. We propose that pharmacological ascorbate may be a general radiosensitizer in cancer therapy and simultaneously a radioprotector of normal tissue.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms221910880